Fluoxetine Treatment of Depression in Down Syndrome
Study Details
Study Description
Brief Summary
The purpose of the study is to do a preliminary assessment of whether fluoxetine is effective, safe, and tolerable for the treatment of depression in adults with Down syndrome.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 4 |
Detailed Description
After being informed about the study and potential risks, all patients or their legal guardians giving written informed consent will be screened for study eligibility. Patients who meet the eligibility requirements will participate in a 16-week, flexibly-dosed, open-label trial of fluoxetine. The dose of fluoxetine will be adjusted over the first 12 weeks of the study and a stable dose will be maintained for the final four weeks of the trial. Adverse effects will be reviewed at each visit and standardized measures of depression will be conducted at weeks 4, 8, 12, and 16.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Fluoxetine Subjects will receive fluoxetine 5 mg each morning at the start of the trial. The dose will be increased by 5 mg every 2 weeks depending on effectiveness and tolerability. The optimal dose will be reached by week 12 of treatment. The minimum starting dose will be 5 mg and the maximum total daily dose will be 30 mg. |
Drug: Fluoxetine
All participants in the study will receive open-label treatment with orally administered fluoxetine for the full duration of the 16-week trial. Fluoxetine is a selective serotonin reuptake inhibitor. It is approved for the management of major depressive disorder in adults.
|
Outcome Measures
Primary Outcome Measures
- Proportion of Participants Who Responded to Treatment at 16 Weeks According to Improvement Item of the Clinical Global Impression-Scale (Response Defined as CGI-I=1 or CGI-I=2) [Week 16]
The Clinical Global Impressions Global Improvement (CGI-I) is designed to take into account all factors to arrive at an assessment of response to treatment. The CGI-I scale ranges from 1 to 7 (1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7= very much worse), with lower scores indicating improvement (1=very much improved; 2=much improved). In this study, the CGI-I will be focused on the treatment target of depression symptom severity. Participants with a CGI-I score of 1 or 2 will be classified as responders.
Secondary Outcome Measures
- Mean 16-Week Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score [Baseline, Week 4, Week 8, Week 12, Week 16]
The MADRS is one of the most frequently used outcome measures in antidepressant efficacy trials and was developed to assess change in depressive symptoms after treatment with antidepressants. It is clinician-rated and consists of 10 items, each rated on a 0-6 scale and summed to determine the total score. A total score of 7-19 is indicative of mild depression, 20-34 of moderate depression, 35-59 of severe depression, and 60 or greater of very severe depression. The MADRS will be conducted at screening, baseline, and each follow-up visit.
- Mean 16-Week Change in Hamilton Depression Rating Scale (HAM-D) Total Score [Baseline, Week 4, Week 8, Week 12, Week 16]
The HAM-D is a clinician-rated scale with scores based on clinical interview and family report. It addresses both somatic and psychological symptoms of depression. Items are rated on either a 5-point scale (0 to 4) or 3-point scale (0 to 2), where higher scores represent increasing severity of depression. The scores of the 17 items are summed to obtain a total score.
- Mean 16-Week Change in Glasgow Depression Scale for people with a Learning Disability (GDS-LD) Total Score [Baseline, Week 4, Week 8, Week 12, Week 16]
The GDS-LD was developed to describe and quantify depressive symptoms in adults with mild-to-moderate learning disabilities. The GDS-LD consists of 20 items scored from 0 to 2. The 20 item scores are summed to obtain the GDS-LD total score. Higher scores are indicative of more severe depression.
- Mean 16-Week Change in Glasgow Depression Scale for people with a Learning Disability Carer Supplement (GDS-CS) Total Score [Baseline, Week 4, Week 8, Week 12, Week 16]
The GDS-CS was developed to describe and quantify depressive symptoms in adults with mild-to-moderate learning disabilities. The GDS-CS consists of 16 items scored from 0 to 2. The 16 item scores are summed to obtain the GDS-CS total score. Higher scores are indicative of more severe depression.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age 18-45 years.
-
Diagnosis of DS confirmed via genetic testing or a clinical diagnosis made by a clinician with significant experience treating patients with DS.
-
Diagnosis of major depressive disorder based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria, confirmed through the Structured Clinical Interview for DSM-5 (SCID-5).
-
Moderately severe depression as evidenced by a Montgomery-Asberg Depression Rating Scale (MADRS) score of 20 or greater at Screen and Baseline. A severity score on the MADRS was chosen as an inclusion criterion since it has been demonstrated to be sensitive to change in adults with MDD.
-
A Clinical Global Impression Severity Item score > 4 (moderate) for depression symptoms at Screen and Baseline.
Exclusion Criteria:
-
Active primary diagnosis of obsessive-compulsive disorder, posttraumatic stress disorder, bipolar disorder, psychosis, or substance use disorder. These disorders are exclusionary since the primary treatment of these disorders may require acute psychosocial or medication treatments that would confound the assessments used in this study. We will evaluate for these disorders using the corresponding SCID-5 modules.
-
Current or previous diagnosis of dementia, or use of medication to treat dementia. Given the potential overlap between depression and dementia symptoms, we want to ensure we are administering fluoxetine to patients with a diagnosis of depression.
-
Presence of any past or present conditions that would make treatment with fluoxetine unsafe. This includes allergy to fluoxetine, liver or kidney disease, unstable heart disease, and/or pregnancy (or being sexually active without using acceptable methods to prevent pregnancy).
-
Use of selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), bupropion, mirtazapine, antipsychotics, lithium, valproic acid, or carbamazepine. Subjects will need to be off these classes of medications for at least 5 elimination half-lives prior to beginning the trial.
-
Use of other psychotropic medications which are ineffective, poorly tolerated, or sub-optimal in terms of dose. A board-certified psychiatrist will assess any other psychotropic medications being used and determine whether they are effective, tolerated, and optimal in terms of dose. If medications are ineffective, poorly tolerated, or sub-optimal in terms of dose, the study psychiatrist will work with the subject and his/her treatment team to either taper or optimize the dose of psychotropic medications prior to study enrollment. Concurrent use of a psychotropic medication (other than SSRIs, SNRIs, TCAs, MAOIs, bupropion, mirtazapine, antipsychotics, lithium, valproic acid, or carbamazepine) will be allowed if the dose has been stable for 30 days and if they meet the criteria of effectiveness, tolerability, and dose.
-
Previous adequate trial of fluoxetine. An adequate trial will be defined as a total daily dose of ≥30 mg for at least 4 weeks. In addition, subjects who developed significant adverse effects during a trial of fluoxetine at any dose or duration will be excluded.
-
Severe or profound intellectual disability based on clinical assessment and review of standardized assessment of cognitive skills. Participants determined to have severe or profound intellectual disability will be excluded.
-
Use of medications that pose a clinically significant risk of a drug-drug interaction with fluoxetine.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Lurie Center for Autism | Lexington | Massachusetts | United States | 02421 |
Sponsors and Collaborators
- Massachusetts General Hospital
Investigators
- Principal Investigator: Robyn P. Thom, MD, Lurie Center for Autism
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2022P000858